Cargando…

The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users

BACKGROUND COVID-19 infection has led to a worldwide pandemic, and new cases are on the rise. Intravenous drug users (IVDU) are presumably at a higher risk of being infected since they have poor personal hygiene, live in groups, and have risky behaviors. The current study aimed to evaluate the serop...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Zahra, Eghtesad, Sareh, Hashemi-Shahri, Seyed Mohammad, Tabatabaei, Seyed Mehdi, Sharafkhah, Maryam, Poustchi, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Association of Gastroerterology and Hepatology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531943/
https://www.ncbi.nlm.nih.gov/pubmed/34712441
http://dx.doi.org/10.34172/mejdd.2021.206
_version_ 1784586972602302464
author Mohammadi, Zahra
Eghtesad, Sareh
Hashemi-Shahri, Seyed Mohammad
Tabatabaei, Seyed Mehdi
Sharafkhah, Maryam
Poustchi, Hossein
author_facet Mohammadi, Zahra
Eghtesad, Sareh
Hashemi-Shahri, Seyed Mohammad
Tabatabaei, Seyed Mehdi
Sharafkhah, Maryam
Poustchi, Hossein
author_sort Mohammadi, Zahra
collection PubMed
description BACKGROUND COVID-19 infection has led to a worldwide pandemic, and new cases are on the rise. Intravenous drug users (IVDU) are presumably at a higher risk of being infected since they have poor personal hygiene, live in groups, and have risky behaviors. The current study aimed to evaluate the seroprevalence of COVID-19 in IVDU in comparison with non-drug users (N-DU). METHODS This cross-sectional study was conducted on 167 IVDU and 134 N-DU. A questionnaire gathering data on demographics, comorbidities, and use of personal protective equipment was administered to all participants. In addition, 5 cc of blood was taken from each individual to test for SARS-CoV-2 specific antibodies (Pishtaz Teb SARS-Cov-2 ELISA kits). RESULTS The mean age of N-DU and IVDU were 38.9 ± 12.9 and 40.38 ± 10.24 years, respectively. COVID-19 seroprevalence in IVDU was 9.7%, and 4.8% in N-DU, but this finding was not statistically significant (p = 0.096). CONCLUSION While the seroprevalence of COVID-19 was not significantly different among the two groups, IVDU should still be considered by policymakers as a high-risk group due to their lifestyle and risky behaviors. Providing personal protective equipment and other means of protection and treatment to this population can help mitigate the spread of and mortality from COVID-19.
format Online
Article
Text
id pubmed-8531943
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Iranian Association of Gastroerterology and Hepatology
record_format MEDLINE/PubMed
spelling pubmed-85319432021-10-27 The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users Mohammadi, Zahra Eghtesad, Sareh Hashemi-Shahri, Seyed Mohammad Tabatabaei, Seyed Mehdi Sharafkhah, Maryam Poustchi, Hossein Middle East J Dig Dis Brief Report BACKGROUND COVID-19 infection has led to a worldwide pandemic, and new cases are on the rise. Intravenous drug users (IVDU) are presumably at a higher risk of being infected since they have poor personal hygiene, live in groups, and have risky behaviors. The current study aimed to evaluate the seroprevalence of COVID-19 in IVDU in comparison with non-drug users (N-DU). METHODS This cross-sectional study was conducted on 167 IVDU and 134 N-DU. A questionnaire gathering data on demographics, comorbidities, and use of personal protective equipment was administered to all participants. In addition, 5 cc of blood was taken from each individual to test for SARS-CoV-2 specific antibodies (Pishtaz Teb SARS-Cov-2 ELISA kits). RESULTS The mean age of N-DU and IVDU were 38.9 ± 12.9 and 40.38 ± 10.24 years, respectively. COVID-19 seroprevalence in IVDU was 9.7%, and 4.8% in N-DU, but this finding was not statistically significant (p = 0.096). CONCLUSION While the seroprevalence of COVID-19 was not significantly different among the two groups, IVDU should still be considered by policymakers as a high-risk group due to their lifestyle and risky behaviors. Providing personal protective equipment and other means of protection and treatment to this population can help mitigate the spread of and mortality from COVID-19. Iranian Association of Gastroerterology and Hepatology 2021-01 2021-03-02 /pmc/articles/PMC8531943/ /pubmed/34712441 http://dx.doi.org/10.34172/mejdd.2021.206 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc/4.0/ This work is published by Middle East Journal of Digestive Diseaes as an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Brief Report
Mohammadi, Zahra
Eghtesad, Sareh
Hashemi-Shahri, Seyed Mohammad
Tabatabaei, Seyed Mehdi
Sharafkhah, Maryam
Poustchi, Hossein
The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
title The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
title_full The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
title_fullStr The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
title_full_unstemmed The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
title_short The Seroprevalence of COVID-19 in Intravenous Drug Users in Comparison to Non-drug Users
title_sort seroprevalence of covid-19 in intravenous drug users in comparison to non-drug users
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531943/
https://www.ncbi.nlm.nih.gov/pubmed/34712441
http://dx.doi.org/10.34172/mejdd.2021.206
work_keys_str_mv AT mohammadizahra theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT eghtesadsareh theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT hashemishahriseyedmohammad theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT tabatabaeiseyedmehdi theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT sharafkhahmaryam theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT poustchihossein theseroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT mohammadizahra seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT eghtesadsareh seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT hashemishahriseyedmohammad seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT tabatabaeiseyedmehdi seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT sharafkhahmaryam seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers
AT poustchihossein seroprevalenceofcovid19inintravenousdrugusersincomparisontonondrugusers